SOURCE: Catalyst Pharmaceutical Partners, Inc.

Catalyst Pharmaceutical Partners, Inc.

October 29, 2013 16:05 ET

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Catalyst Pharmaceutical Partners, Inc. to Contact the Firm

NEW YORK, NY--(Marketwired - Oct 29, 2013) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Catalyst Pharmaceutical Partners, Inc. ("Catalyst" or the "Company") (NASDAQ: CPRX) of the December 24, 2013 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Catalyst and certain executives.

A complaint has been filed on behalf of all persons who purchased Catalyst securities between October 31, 2012 and October 18, 2013 (the "Class Period") in the Southern District of Florida.

The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.

Specifically, the action alleges that throughout the Class Period Catalyst issued false and/or misleading statements and failed to disclose material facts regarding Firdapse, a drug candidate that the Company purported would be used to treat Lambert-Eaton Myasthenic Syndrome ("LEMS").

In fact, prior to the market open on October 18, 2013, an article in The Street revealed that another pharmaceutical company has provided an equivalent drug free of charge for the past 20 years.

Following this news, the Company's stock declined $0.71 per share, or over 27%, to close at $1.90 per share on October 18, 2013.

Request more information now by clicking here: www.faruqilaw.com/CPRX. There is no cost or obligation to you.

Take Action

If you invested in Catalyst stock or options between October 31, 2012 and October 18, 2013 and would like to discuss your legal rights, visit www.faruqilaw.com/CPRX. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Catalyst's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Contact Information

  • FARUQI & FARUQI, LLP
    369 Lexington Avenue, 10th Floor
    New York, NY 10017
    Attn: Richard Gonnello, Esq.
    Email Contact
    Francis McConville, Esq.
    Email Contact
    Telephone: (877) 247-4292 or (212) 983-9330